Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study
Moa Lugner, Naveed Sattar, Mervete Miftaraj, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes
Alison K. Wright, Matthew Carr, Evangelos Kontopantelis, et al.
Diabetes Care (2022) Vol. 45, Iss. 4, pp. 909-918
Open Access | Times Cited: 100
Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies
Irene Caruso, Angelo Cignarelli, Gian Pio Sorice, et al.
Metabolites (2022) Vol. 12, Iss. 2, pp. 183-183
Open Access | Times Cited: 63
Renal effects of GLP-1 receptor agonists and tirzepatide in individuals with type 2 diabetes: seeds of a promising future
Irene Caruso, Francesco Giorgino
Endocrine (2024) Vol. 84, Iss. 3, pp. 822-835
Open Access | Times Cited: 14
Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study
Phyo T. Htoo, Helen Tesfaye, Sebastian Schneeweiß, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 12
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium–Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure
Giovanna Gallo, Massimo Volpe
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2484-2484
Open Access | Times Cited: 10
Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study
Marta Baviera, Andreana Foresta, Pierluca Colacioppo, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 29
Sodium‐glucose cotransporter‐2 inhibitors and kidney outcomes in real‐world type 2 diabetes populations: A systematic review and meta‐analysis of observational studies
Anna Forbes, Rebecca Suckling, William Hinton, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 8, pp. 2310-2330
Closed Access | Times Cited: 19
Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care
Gian Paolo Fadini, Enrico Longato, Mario Luca Morieri, et al.
Diabetologia (2024) Vol. 67, Iss. 11, pp. 2585-2597
Open Access | Times Cited: 7
Effect of frailty on effectiveness and safety of GLP-1 receptor agonists versus SGLT2 inhibitors in people with type 2 diabetes in Taiwan: a retrospective, nationwide, longitudinal study
Fei‐Yuan Hsiao, Elise Tan, Lin-Chieh Meng, et al.
The Lancet Healthy Longevity (2024), pp. 100621-100621
Open Access | Times Cited: 6
Lower limb amputations: protection with GLP-1 receptor agonists rather than increased risk with SGLT2 inhibitors?
André Scheen
Diabetes & Metabolism (2022) Vol. 48, Iss. 2, pp. 101325-101325
Closed Access | Times Cited: 27
Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practice
Edouard L. Fu, Catherine M. Clase, Roemer J. Janse, et al.
International Journal of Cardiology (2022) Vol. 352, pp. 172-179
Open Access | Times Cited: 22
Atherosclerotic cardiovascular disease risk stratification and management in type 2 diabetes: review of recent evidence-based guidelines
Pierre Gourdy, François Schiele, Jean‐Michel Halimi, et al.
Frontiers in Cardiovascular Medicine (2023) Vol. 10
Open Access | Times Cited: 12
Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong
David Tak Wai Lui, Eric Ho Man Tang, Tingting Wu, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 11
Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies
André Scheen
Diabetes & Metabolism (2023) Vol. 49, Iss. 5, pp. 101474-101474
Closed Access | Times Cited: 11
Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists and Sodium/Glucose Cotransporter 2 Inhibitors in Preventing Chronic Kidney Failure and Mortality in Patients With Type 2 Diabetes and CKD
Yen‐Chieh Lee, Li-Chiu Wu, Vin‐Cent Wu, et al.
American Journal of Kidney Diseases (2025)
Closed Access
Comparison of cardiovascular outcomes of new antihyperglycemic agents in Type 2 Diabetes Mellitus: a meta‐analysis
Zijing Zhou, Min Zheng, Zhihong Zuo, et al.
ESC Heart Failure (2024) Vol. 11, Iss. 3, pp. 1647-1656
Open Access | Times Cited: 3
SGLT2 Inhibitors vs GLP-1 Receptor Agonists and Clinical Outcomes in Patients With Diabetes With/Without Atrial Fibrillation
Yi‐Hsin Chan, Tze-Fan Chao, Shao-Wei Chen, et al.
The Journal of Clinical Endocrinology & Metabolism (2024)
Open Access | Times Cited: 3
Comparison of estimated glomerular filtration rate change with sodium‐glucose cotransporter‐2 inhibitors versus glucagon‐like peptide‐1 receptor agonists among people with diabetes: A propensity‐score matching study
Yuta Suzuki, Hidehiro Kaneko, Hajime Nagasawa, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 6, pp. 2422-2430
Closed Access | Times Cited: 3
Néphroprotection et diabète de type 2 : regards croisés en 2025 sur quatre (nouvelles) classes thérapeutiques d’intérêt
Martin Buysschaert, J. Abodo, Jamal Belkhadir, et al.
Médecine des Maladies Métaboliques (2025)
Closed Access
Impact of Glucagon-like peptide 1 receptor agonists on peripheral arterial disease in people with diabetes mellitus: A narrative review
Alexandros L. Liarakos, Anastasios Tentolouris, Alexandros Kokkinos, et al.
Journal of Diabetes and its Complications (2022) Vol. 37, Iss. 2, pp. 108390-108390
Closed Access | Times Cited: 15
An Overview of Similarities and Differences in Metabolic Actions and Effects of Central Nervous System Between Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and Sodium Glucose Co-Transporter-2 Inhibitors (SGLT-2is)
Song Wen, Thiquynhnga Nguyen, Min Gong, et al.
Diabetes Metabolic Syndrome and Obesity (2021) Vol. Volume 14, pp. 2955-2972
Open Access | Times Cited: 19
The comparative cardiovascular and renal effectiveness of sodium‐glucose co‐transporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: A Scandinavian cohort study
Peter Ueda, Viktor Wintzell, Elisabeth Dahlqwist, et al.
Diabetes Obesity and Metabolism (2021) Vol. 24, Iss. 3, pp. 473-485
Open Access | Times Cited: 19
Diabetes, Vascular Aging and Stroke: Old Dogs, New Tricks?
Theano Penlioglou, Anca Pantea Stoian, Νικόλαος Παπάνας
Journal of Clinical Medicine (2021) Vol. 10, Iss. 19, pp. 4620-4620
Open Access | Times Cited: 18
A review of the latest real‐world evidence studies in diabetic kidney disease: What have we learned about clinical practice and the clinical effectiveness of interventions?
Fabrice Bonnet, Mark E. Cooper, Laetitia Koppe, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. S6, pp. 55-65
Open Access | Times Cited: 2
SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists Effects on Kidney and Clinical Outcomes in Veterans with Type 2 Diabetes
Candis M. Morello, Linda Awdishu, Stepfanie Lam, et al.
Kidney360 (2024) Vol. 5, Iss. 11, pp. 1633-1643
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top